Leerink Partners maintained a Market Perform rating on Myriad Genetics (NASDAQ: MYGN), and cut the price target to $41.00 (from ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS Change Analyst EPS View Analyst PT Change

Myriad Genetics (MYGN) Beat But Not By Enough, Mizuho Says; PT to $34May 4, 2016 6:55 AM After-Hours Stock Movers 05/03: (GKOS) (ETSY) (NTRI) (MDVN) Higher; (CRAY) (SYRG) (GLUU) (RLYP) Lower (more...)May 3, 2016 6:26 PM Myriad Genetics (MYGN) Tops Q3 EPS by 3c, Offers Q4 & FY GuidanceMay 3, 2016 4:07 PM Myriad Genetics Reports Fiscal Third-Quarter 2016 Financial ResultsMay 3, 2016 4:07 PM Trading Radar for 5/3: CBS (CBS), GrubHub (GRUB), Etsy (ETSY), USANA (USNA), WellCare (WCG) ReportMay 2, 2016 2:24 PM Myriad Genetics to Present at the Bank of America Health Care ConferenceMay 2, 2016 7:05 AM